Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Study Identifier
P15-692
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Statistical Analysis Plan
Available Language(s): English
Protocol
Available Language(s): English
Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Dermatology - Hidradenitis Suppurativa (HS)
  • Study Drug
  • Adalimumab
  • Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 99 Years

    Protocol Summary

    The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.

    Study Locations

    Location
    Status
    Location
    Universitetssjukhuset Linköping
    Linkoping, Västra Götaland County, Sweden, 581 85
    Status
    Not applicable
    Location
    Hallands Hospital Halmstad
    Halmstad, Sweden, 301 85
    Status
    Not applicable
    Location
    Blekinge Hospital
    Karlskrona, Sweden, SE-37185
    Status
    Not applicable
    Location
    Skaraborgs Hospital
    Skövde, Sweden, 541 85
    Status
    Not applicable
    Location
    Karolinska Univ Sjukhuset
    Solna, Sweden, 17176
    Status
    Not applicable
    Location
    Kungsholmens Hudklinik
    Stockholm, Sweden, 112 51
    Status
    Not applicable
    Showing {first} - {last} of {total} Results